The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Lysosomal Biomarkers Program, 2023Developing a Targeted Proteomic Test to Monitor Blood Samples for Lysosomal Signatures of Parkinson’s Disease
Study Rationale: Lysosomes are structures that help clear cells of molecular debris, and lysosomal dysfunction has been linked to neurodegeneration in Parkinson’s disease (PD). In this study, we will...
-
Lysosomal Biomarkers Program, 2023Measurement of Neuronal Extracellular Vesicles as a Blood-based Biomarker for Lysosomal Function
Study Rationale: Parkinson’s disease (PD) is associated with the aggregation of toxic proteins, a buildup due partly to the reduced ability of lysosomes to degrade these proteins. Improving lysosome...
-
Lysosomal Biomarkers Program, 2023Development of Autophagy-lysosome Biomarkers for Parkinson’s Disease Using Stem Cell-derived Neurons and Biofluids
Study Rationale: Genetic, molecular, and pathological studies have highlighted the role of dysfunctional mechanisms for clearing cellular debris — called autophagy-lysosome pathways — in the...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Evaluating the Impact of LRRK2 Mutation on Lysosomal Function in Macrophages
Study Rationale: Mutations in LRRK2 are associated with inherited forms of Parkinson’s disease (PD). LRRK2 is a lysosomal protein that is produced in immune cells, such as macrophages. These cells are...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Investigating the Molecular Basis of Neurodegeneration in GBA-associated Parkinson's Disease
Study Rationale: Mutations in GBA1, the gene that encodes the enzyme glucocerebrosidase (GCase), are among the most common genetic risk factor for the development of Parkinson’s disease (PD). GCase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.